FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immunoglobulin topics
Immunoglobulin
Antibodies
Immunoglobulins
Recombinant
Polypeptide
Nucleic Acid
Cancer Cell
G Proteins
Prophylactic
Metalloprotein
Monoclonal
Cancer Cells
Metastasis
Extracellular
Adhesion Molecule

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunoglobulin patents



      
           
This page is updated frequently with new Immunoglobulin-related patent applications. Subscribe to the Immunoglobulin RSS feed to automatically get the update: related Immunoglobulin RSS feeds. RSS updates for this page: Immunoglobulin RSS RSS


Date/App# patent app List of recent Immunoglobulin-related patents
07/24/14
20140206019
 Fc-function assay patent thumbnailFc-function assay
The present invention discloses a method of assaying fc-function in an immunoglobulin containing sample by contacting the sample, in the presence of a complement, with red blood cells modified to incorporate a f-s-l peptide-lipid construct. The f-s-l peptide construct comprises a functional group (f) that is a target antigen for a complement activating immunoglobulin, a spacer group (s) covalently linking f to l and a lipid group (l).
07/24/14
20140205607
 Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing patent thumbnailFocused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing
Antibody vrc01 represents a human immunoglobulin that neutralizes—˜90% of diverse hiv-1 isolates. To understand how such broadly neutralizing hiv-1 antibodies develop and recognize the viral envelope, we used x-ray crystallography and 454 pyrosequencing to characterize additional antibodies from hiv-1-infected individuals.
07/24/14
20140205597
 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains patent thumbnailTechniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given isv will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ada immunoassay). Such predictive assays could for example be used to test whether a given isv could have a tendency to give rise to such protein interference and/or such a signal; to select isv's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an isv will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an isv so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving isv's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an isv that remove or reduce its tendency to give rise to such protein interference or such a signal; isv's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved isv's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal..
07/24/14
20140205560
 Multimeric il-15 soluble fusion molecules and methods of making and using same patent thumbnailMultimeric il-15 soluble fusion molecules and methods of making and using same
The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (il-15) polypeptide or a functional fragment thereof.
07/17/14
20140200331
 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof patent thumbnailEngineered immunoglobulin heavy chain-light chain pairs and uses thereof
The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the ch1 and/or cl domains, amino acid modifications in the vh and/or vl domains or a combination thereof.
07/17/14
20140200159
 Identifying antigen clusters for monitoring a global state of an immune system patent thumbnailIdentifying antigen clusters for monitoring a global state of an immune system
Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.. .
07/17/14
20140199316
 Methods of treating complications and disorders associated with g-csf administration patent thumbnailMethods of treating complications and disorders associated with g-csf administration
The present embodiments relate to novel uses of mpo inhibitors and inhibitors of mpo and e-selectin binding. In some embodiments, methods are provided for treating g-csf-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits e-selectin receptor/ligand interaction or inhibits mpo activity.
07/17/14
20140199295
 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains patent thumbnailTechniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given isv will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ada immunoassay). Such predictive assays could for example be used to test whether a given isv could have a tendency to give rise to such protein interference and/or such a signal; to select isv's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an isv will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an isv so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and/or improving isv's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an isv that remove or reduce its tendency to give rise to such protein interference or such a signal; isv's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved isv's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal..
07/10/14
20140193838
 Method for measuring sialic acid in immunoglobulin g and immunoglobulin g anti-double-stranded dna antibodies patent thumbnailMethod for measuring sialic acid in immunoglobulin g and immunoglobulin g anti-double-stranded dna antibodies
A method for measuring the amount of sialic acid in immunoglobulin g and immunoglobulin g anti-ds dna antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin g in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin g.
07/10/14
20140193407
 Drug fusions and conjugates patent thumbnailDrug fusions and conjugates
The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and glp and/or exendin molecules.
07/10/14
20140193399
Anti-cd3 antibodies and methods of use thereof
The present invention is related to antibodies directed to the antigen cd3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to cd3.
07/10/14
20140193359
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2.
07/03/14
20140187753
Hetero-dimeric immunoglobulins
The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.. .
07/03/14
20140186345
Method of administering an antibody
Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month..
07/03/14
20140186293
Immunoglobulin-bound extracellular vesicles and uses thereof
Provided are methods of isolating igg-bound (e.g., igg-bound or protein g-recognized igg-bound) extracellular vesicles from a sample containing a biological fluid from a subject, where the igg (e.g., igg2 or protein g-recognized igg) is bound to an antigen present on the surface of the extracellular vesicle and the igg (e.g., igg2 or protein g-recognized igg) is an endogenous antibody. Also provided are methods of diagnosing a cancer in a subject that include detecting the presence of one or more tumor antigens in an isolated igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle, and methods of treating a subject that include administering one or more cancer therapeutics to a subject having an igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle that contains one or more tumor antigens..
06/26/14
20140179898
Mutated protein of protein a having reduced affinity in acidic region and antibody-capturing agent
A modified protein of an extracellular domain of protein a, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein a, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein a bound with the fc region of immunoglobulin g, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the fc region and have a 20% or more ratio of exposed surface area, by histidine residues.
06/26/14
20140179550
Immunoglobulin fc libraries
Methods and composition for the screening and isolation of aglycosylated antibody fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated fc domains that bind to fc receptors or preferentially bind to particular fc receptors are described.
06/26/14
20140179547
Methods for the generation of multispecific and multivalent antibodies
The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a kappa constant domain and the other of a lambda constant domain.
06/26/14
20140178916
Method of neonatal serological diagnosis
The present invention provides a method for determining the amino acid polymorphisms of heavy gamma chain of immunoglobulins g by a proteomic approach. This method distinguishes the immunoglobulins of the mother and those of the newborn in a blood sample obtained during the first months of the child's life.
06/26/14
20140178869
Detection of immunoglobulin light chain restriction by rna in situ hybridization
The invention provides a method for detecting immunoglobulin light chain restriction and clonality in b cells by obtaining a sample of b cells from a subject; conducting a duplex in situ hybridization assay on the sample using (i) at least one probe set which is designed to specifically hybridize to immunoglobulin kappa chain constant region (igkcr) rna; and (ii) at least one probe set which is designed to specifically hybridize to immunoglobulin lambda chain constant region (iglcr) rna; detecting signal associated with hybridized igkcr probe and signal associated with hybridized iglcr probe in a population of b cells in the sample; and determining a pattern of signal associated with hybridized igkcr probe and hybridized iglcr probe within individual cells in the b cell population, wherein the pattern of signal within individual cells indicates the presence or absence of light chain restriction and clonality of the b cells.. .
06/26/14
20140178390
Biological materials related to cxcr7
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting cxcr7 mediated tumour growth..
06/26/14
20140178364
Compositions and methods for targeting type 1 interferon producing cells
The present disclosure provides a method for treating lupus, sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (il-3rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p dcs) and basophils to which it binds.. .
06/26/14
20140178361
Method for polyclonal immunoglobulin g production by human b cells
This application relates to an in vitro method of producing a polyclonal igg preparation. The method comprises (i) placing a polyclonal b-cell population enriched in igg-secreting b cells in a culture medium; and (ii) culturing the polyclonal b-cell population under conditions enabling the production of the polyclonal igg preparation from the polyclonal b-cell population.
06/26/14
20140178294
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2.
06/19/14
20140171621
Galectin-immunoglobulin chimeric molecules
Described are galectin-1/ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.. .
06/19/14
20140170171
Targeted cytokine for treatment of musculoskeletal diseases
Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a tgf-beta associated with immunoglobulins (such as iggs) or functional portions thereof including fc portions, such as by non-covalent bonds.
06/19/14
20140170169
Blocking antibody for transplantation
A method can include administering a donor-specific human leukocyte antigen antibody to a tissue transplant recipient where the antibody is an immunoglobulin g subclass 4 antibody (g4). Various other examples of devices, assemblies, systems, methods, etc., are also disclosed..
06/19/14
20140170137
Therapeutic canine immunoglobulins and methods of using same
A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen.
06/12/14
20140161817
Stable dual variable domain immunoglobulin protein formulations
The invention provides stable aqueous formulations comprising an aqueous stable dual variable domain immunoglobulin (as-dvd-ig) protein. The invention also provides stable lyophilized formulations comprising a lyophilized stable dual variable domain immunoglobulin (ls-dvd-ig) protein..
06/12/14
20140161790
Engineered immunoglobulins with extended in vivo half-life
The present application relates to immunoglobulin compositions with improved half-life, and their application, particularly for therapeutic purposes.. .
06/05/14
20140155580
Transgenic aves producing human polyclonal antibodies
In the preferred embodiment, the human immunoglobulin locus is at least as large as the native human locus and exhibits functional class switching to yield igg isotype antibodies. In addition to monoclonal antibodies secreted from immortalized b cell populations, polyclonal antibodies may be obtained from eggs laid by the transgenic chickens of the invention..
06/05/14
20140154257
Materials and methods for diagnosing and treating asthma and dietary fru-ages related disorders including auto-immune and other diseases found to be associated with elevated rage. the specification describes methods to identify and make dietary derived advanced glycation end-products, known as fru-ages, fru-age-haptens, and fru-age immune complexes, and to make monoclonal and polyclonal antibodies to this plurality of bio-molecules for use in immunoassays and for use as therapeutic agents
Present invention is directed to materials and methods useful in diagnosing gut derived advanced glycation end-products (“fru-ages”) associated with asthma, juvenile arthritis and other pro-inflammatory chronic diseases. Fru-ages arise from the interaction [fructosylation] between elevated gastro-intestinal excess free fructose and other food/bio-molecules including peptides, proteins, lipids, lipo/glycoproteins and others in the digestive tract.
06/05/14
20140154256
Anti-il1alpha/beta dual variable domain immunoglobulin and uses thereof
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
06/05/14
20140154254
Heterodimeric immunoglobulins
The present application is directed to heterodimeric antibodies and methods of use.. .
06/05/14
20140154242
Immunoglobulin variants and uses thereof
The invention provides humanized and chimeric anti-cd20 antibodies for treatment of cd20 positive malignancies and autoimmune diseases.. .
05/29/14
20140147435
Nogo-a neutralizing immunoglobulins for the treatment of neurological diseases
The present invention relates to antibodies to nogo, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.. .
05/22/14
20140141995
Immunoassay
The invention provides a method of quantifying multiple antigen-specific immunoglobulins in a test sample, the method comprising utilising a serial dilution of anti-immunoglobulin antibodies, fragments or derivatives thereof, immobilised on a solid support in combination with a serial dilution of a reference sample of immunoglobulin to generate multiple binding capacity curves. Such binding capacity curves are matched to specific dose response curves generated for each specific antigen to be tested using serum samples of known reactivity to those antigens to provide a calibration system that enables more accurate analysis of antigen-specific immunoglobulin in a sample.
05/22/14
20140141507
Method for the production of immunoglobulin single variable domains
Methods are provided for the expression of immunoglobulin variable domains that are secreted into the culture medium. The methods provide for the production of homogeneous immunoglobulin variable domains in which the proportion of product-related variants that comprise, at the n-terminus, at least one redundant amino acid residue derived from the secretion signal is strongly reduced or absent..
05/22/14
20140141446
Aptamers that are specific for immunoglobulin-binding cell wall proteins
The invention relates to an aptamer that binds to protein a, g or l, protein a-, g- or l-containing substances, and also to protein a-, g- or l-containing microorganisms, in particular staphylococcus aureus, streptococcus or peptostreptococcus, methods for detection and enrichment of protein a, g or l, protein a-, g- or l-containing substances or protein a-, g- or l-containing microorganisms in which the aptamer is used, and also a kit, a biosensor, a lateral flow assay device and a measuring instrument which contain such an aptamer and can be used in said methods.. .
05/22/14
20140141022
Single-chain multivalent binding proteins with effector function
Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.. .
05/22/14
20140141021
Method for preparing a concentrate of polyvalent immunoglobulin
The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained.. .


Popular terms: [SEARCH]

Immunoglobulin topics: Immunoglobulin, Antibodies, Immunoglobulins, Recombinant, Polypeptide, Nucleic Acid, Cancer Cell, G Proteins, Prophylactic, Metalloprotein, Monoclonal, Cancer Cells, Metastasis, Extracellular, Adhesion Molecule

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunoglobulin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunoglobulin with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2908

3888

70 - 0 - 76